関連レポート

関節リウマチ治療薬の世界市場：2031年予測

出版元：Transparency Market Research  出版元について

発行年：2024年2月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 185ページになります。

商品コード：TMR229

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

変形性膝関節症治療薬の世界市場規模は2022年で86億ドル、2031年に177億ドル、市場の平均年成長率は8.5%に増加する見通しです。

当レポートでは、変形性膝関節症治療薬の市場予測-2031年、各種セグメント別市場分析(投与経路別、流通経路別、国地域別、等)、パイプライン分析、市場シェア分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■変形性膝関節症治療薬の世界市場予測2017-2031年
・市場規模(US$)

■薬剤クラス別、市場-2031年
副腎皮質ステロイド
非ステロイド性抗炎症薬
ビスコサプリメント剤
※(市場規模US$)

■投与経路別、市場-2031年
経口
非経口
局所
※(市場規模US$)

■流通経路別、市場-2031年
病院薬局
小売薬局
オンライン薬局
※(市場規模US$)

■主要国地域別市場-2031年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド、
・その他アジア太平洋
南米
・ブラジル、メキシコ
・その他南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス（促進要因、障壁、機会）
パイプライン分析
COVID-19の影響分析
競合状況
市場シェア分析

■変形性膝関節症治療薬の主要企業プロフィール動向
Horizon Pharma plc
Pfizer Inc.
サノフィ株式会社
Anika Therapeutics, Inc.
Ferring B.V.
Bioventus, Inc.
中外製薬株式会社
Alkem Laboratories
Flexion Therapeutics, Inc.
Zimmer Biomet Holdings, Inc.
（全185頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Osteoarthritis Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Osteoarthritis Drugs Market Analysis and Forecast, 2017–2031

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Osteoarthritis Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Corticosteroids
6.3.2. NSAIDs & Others
6.3.3. Viscosupplementation Agents
6.4. Market Attractiveness Analysis, by Drug Class

7. Global Osteoarthritis Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Topical
7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Osteoarthritis Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Osteoarthritis Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Osteoarthritis Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Corticosteroids
10.3.2. NSAIDs & Others
10.3.3. Viscosupplementation Agents
10.4. Market Value Forecast, by Route of Administration, 2017–2031
10.4.1. Oral
10.4.2. Parenteral
10.4.3. Topical
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Route of Administration
10.7.3. By Distribution Channel
10.7.4. By Country

11. Europe Osteoarthritis Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Corticosteroids
11.3.2. NSAIDs & Others
11.3.3. Viscosupplementation Agents
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Parenteral
11.4.3. Topical
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region

12. Asia Pacific Osteoarthritis Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Corticosteroids
12.3.2. NSAIDs & Others
12.3.3. Viscosupplementation Agents
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Topical
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region

13. Latin America Osteoarthritis Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Corticosteroids
13.3.2. NSAIDs & Others
13.3.3. Viscosupplementation Agents
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Topical
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region

14. Middle East & Africa Osteoarthritis Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Corticosteroids
14.3.2. NSAIDs & Others
14.3.3. Viscosupplementation Agents
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Topical
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Horizon Pharma plc
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Pfizer Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanofi
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Anika Therapeutics, Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Ferring B.V.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Bioventus, Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Chugai Pharmaceutical Industries Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Alkem Laboratories
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Flexion Therapeutics, Inc.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Zimmer Biomet Holdings, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview

List of Tables

Table 01: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 03: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 07: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 08: North America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 11: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 12: Europe Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 16: Asia Pacific Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 19: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 20: Latin America Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 23: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 24: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Osteoarthritis Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031

Figure 02: Global Osteoarthritis Drugs Market Revenue (US$ Mn), by Drug Class, 2022

Figure 03: Global Osteoarthritis Drugs Market Value Share, by Drug Class, 2022

Figure 04: Global Osteoarthritis Drugs Market Revenue (US$ Mn), by Route of Administration, 2022

Figure 05: Global Osteoarthritis Drugs Market Value Share, by Route of Administration, 2022

Figure 06: Global Osteoarthritis Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022

Figure 07: Global Osteoarthritis Drugs Market Value Share, by Distribution Channel, 2022

Figure 08: Global Osteoarthritis Drugs Market Value Share, by Region, 2022

Figure 09: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, 2023–2031

Figure 10: Global Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

Figure 11: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 12: Global Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 13: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 14: Global Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 15: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 16: Global Osteoarthritis Drugs Market Value Share Analysis, by Region, 2022–2031

Figure 17: Global Osteoarthritis Drugs Market Attractiveness Analysis, by Region, 2023–2031

Figure 18: North America Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Country, 2023–2031

Figure 20: North America Osteoarthritis Drugs Market Value Share Analysis, by Country, 2022–2031

Figure 21: North America Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

Figure 22: North America Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 23: North America Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 24: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 25: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 26: North America Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 27: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Europe Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 30: Europe Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

Figure 31: Europe Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 32: Europe Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 33: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 34: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 35: Europe Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 36: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 39: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

Figure 40: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 41: Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 42: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 43: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 44: Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 45: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 47: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 48: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

Figure 49: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 50: Latin America Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 51: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 52: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 53: Latin America Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 54: Middle East & Africa Osteoarthritis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 56: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 57: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2022–2031

Figure 58: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 59: Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 60: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 61: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 62: Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

△ 一番上に戻る